Genomic Health Earnings: Here’s Why the Stock is Down Now
Genomic Health Inc. (NASDAQ:GHDX) had a loss and met Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are down 0.13%.
Genomic Health Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share decreased to $-0.03 in the quarter versus EPS of $0.02 in the year-earlier quarter.
Revenue: Rose 7.92% to $63.1 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: Genomic Health Inc. reported adjusted EPS loss of $0.03 per share. By that measure, the company missed the mean analyst estimate of $-0.03. It beat the average revenue estimate of $62.9 million.
Quoting Management: “The management of DCIS has been variable in the absence of reliable methods to select patients for treatment with surgical excision alone, without radiation. The DCIS Score is a new tool that can help physicians and patients make more informed decisions,” said Lawrence J. Solin, M.D., FACR, FASTRO, principal investigator for this study and chair of the Department of Radiation Oncology at Einstein Medical Center in Philadelphia, Pennsylvania. ”
Key Stats (on next page)…